Challenges Seen With Novel Agents in Multiple Myeloma
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
At the start of her practice, lenalidomide (Revlimid) and bortezomib (Velcade) were the only 2 novel agents available for patients with myeloma. Now, there are monoclonal antibodies, checkpoint inhibitors, CAR T cells, and many more.
With so many novel and targeted agents appearing in the treatment landscape, it is hard to keep up with all of the latest data for these drugs. In most cases, there is still not enough information available on the overall survival or progression-free survival with these drugs, Madduri says.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
